The effect of psoralen plus ultraviolet A in vitro in HUT-78 enhances by 5-aminolevulinic acid.
BACKGROUND
Sezary syndrome and mycosis fungoides are forms of cutaneous T-cell lymphoma, and in the early stage of these diseases psoralen plus ultraviolet A (PUVA) is one of the treatments of choice. Photodynamic therapy using 5-aminolevulinic acid (ALA-PDT) is an effective, non-invasive, and safe treatment for most superficial skin cancers. In order to obtain greater efficacy of PUVA, we investigated the synergistic anti-tumor effects of ALA-PDT and PUVA using 8-methoxypsoralen (8-MOP) and a UVA lamp.


METHODS
The in vitro effects of PUVA and ALA-PDT and their combination in HUT-78 cell line from human SS were determined by MTT assay.


RESULTS
In our results, cell proliferation compared with controls was inhibited to 53.2% with UVA alone, 52.3% with 1 microM 8-MOP, 43.8% with 100 microM ALA, and 19.2% with combined 8-MOP and ALA.


CONCLUSIONS
Combined use of ALA and PUVA using 8-MOP and UVA lamps, which are widespread in Japan, had a strong anti-tumor effect in vitro. Combined treatment with ALA-PDT and PUVA using a UVA lamp appears to have a strong treatment effect.
Akita
Yoichi
Y
Department of Dermatology, Aichi Medical University School of Medicine, Nagakute, Japan. 106039@gk.amu.aichi-med-u.ac.jp
Watanabe
Daisuke
D
Yanagishita
Takeshi
T
Kuhara
Tomoe
T
Kawamura
Chiharu
C
Masuda
Yuko
Y
Kawada
Morihiro
M
Nakaseko
Hirono
H
Tamada
Yasuhiko
Y
Matsumoto
Yoshinari
Y
D000622:Aminolevulinic Acid / Q000008:administration & dosage*; D045744:Cell Line, Tumor / Q000187:drug effects / Q000528:radiation effects; D049109:Cell Proliferation / Q000187:drug effects / Q000528:radiation effects; D004357:Drug Synergism; D006801:Humans; D008730:Methoxsalen / Q000008:administration & dosage*; D009182:Mycosis Fungoides / Q000188:drug therapy / Q000473:pathology; D011701:PUVA Therapy; D017319:Photosensitizing Agents / Q000008:administration & dosage*; D012751:Sezary Syndrome / Q000188:drug therapy / Q000473:pathology; D012878:Skin Neoplasms / Q000188:drug therapy*; D014466:Ultraviolet Rays
D017319:Photosensitizing Agents; D000622:Aminolevulinic Acid; D008730:Methoxsalen